Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study)
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs Meningococcal vaccine group B (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Acronyms ProPositive
- 08 Apr 2019 Status changed from not yet recruiting to recruiting.
- 15 Jan 2019 Planned initiation date changed from 1 Sep 2018 to 1 Feb 2019.
- 28 Sep 2018 New trial record